Date |
|
Jul 5, 2016 |
CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial |
Jul 11, 2016 |
CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy |
Aug 1, 2016 |
CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial |
Aug 10, 2016 |
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results |
Aug 23, 2016 |
CEL-SCI Announces $5 Million Registered Direct Offering |
Aug 29, 2016 |
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering |
Sep 2, 2016 |
CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial |
Sep 6, 2016 |
CEL-SCI Announces Resignation of its Founder for Health Reasons |
Sep 26, 2016 |
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study |
Oct 21, 2016 |
CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial |